Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 3
1983 6
1984 1
1985 3
1986 5
1987 2
1988 2
1990 1
1991 1
1992 3
1993 6
1994 2
1995 2
1996 2
1997 2
1998 4
1999 3
2000 1
2002 8
2003 2
2004 3
2005 6
2006 2
2007 7
2008 6
2009 7
2010 4
2011 5
2012 14
2013 7
2014 8
2015 5
2016 1
2017 5
2018 7
2019 9
2020 5
2021 4
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Valproic Acid-Associated Hyperammonemia: A Systematic Review.
Wong YJ, Fan J, Wan A, Mihic T, Gnyra M. Wong YJ, et al. J Clin Psychopharmacol. 2023 May-Jun 01;43(3):283-294. doi: 10.1097/JCP.0000000000001689. J Clin Psychopharmacol. 2023. PMID: 37126830
BACKGROUND: Hyperammonemia is an adverse effect that poses clinical uncertainty around valproic acid (VPA) use. ...There was insufficient data to support routine monitoring of ammonia level for VPA-associated hyperammonemia. CONCLUSIONS: Valproic …
BACKGROUND: Hyperammonemia is an adverse effect that poses clinical uncertainty around valproic acid (VPA) use. ...Ther …
Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome.
Camacho J, Rioseco-Camacho N. Camacho J, et al. 2012 May 31 [updated 2020 Feb 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2012 May 31 [updated 2020 Feb 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 22649802 Free Books & Documents. Review.
Routine assessment of plasma ammonia concentration, plasma and urine amino acid concentrations, urine organic acids, and urine orotic acid based on age and history of adherence and metabolic control. ...Periodic neurologic evaluation to monitor for neurologic …
Routine assessment of plasma ammonia concentration, plasma and urine amino acid concentrations, urine organic acids, and urine orotic …
Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
Duman B, Can KC, Ağtaş-Ertan E, Erdoğan S, İlhan RS, Doğan Ö, Kumbasar H, Çamsarı UM. Duman B, et al. Gen Hosp Psychiatry. 2019 Jul-Aug;59:67-72. doi: 10.1016/j.genhosppsych.2019.05.005. Epub 2019 May 31. Gen Hosp Psychiatry. 2019. PMID: 31276904
OBJECTIVE: Valproic acid (VPA)-induced hyperammonemia (VIH), is an increase in blood ammonia levels without any alteration of hepatic enzymes, which can occur during VPA treatment. ...No association was found between cognitive functions and hyperammonemia …
OBJECTIVE: Valproic acid (VPA)-induced hyperammonemia (VIH), is an increase in blood ammonia levels without any alterat …
Hyperammonemia associated with valproic acid concentrations.
Vázquez M, Fagiolino P, Maldonado C, Olmos I, Ibarra M, Alvariza S, Guevara N, Magallanes L, Olano I. Vázquez M, et al. Biomed Res Int. 2014;2014:217269. doi: 10.1155/2014/217269. Epub 2014 Apr 29. Biomed Res Int. 2014. PMID: 24868521 Free PMC article.
As a high correlation between salivary valproic acid levels and plasma ultrafiltrate levels was found in humans, saliva becomes a promising monitoring fluid in order to study valproic acid pharmacokinetics and its toxic effect. Extended-release (twice …
As a high correlation between salivary valproic acid levels and plasma ultrafiltrate levels was found in humans, saliva become …
Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
Thomas KL, La AQ, Punia S, Doroudgar S, Perry PJ. Thomas KL, et al. Ann Clin Psychiatry. 2016 Feb;28(1):37-42. Ann Clin Psychiatry. 2016. PMID: 26855984
BACKGROUND: Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients. ...Patients completed a batte …
BACKGROUND: Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and th …
Valproate-induced hyperammonemic encephalopathy.
Verrotti A, Trotta D, Morgese G, Chiarelli F. Verrotti A, et al. Metab Brain Dis. 2002 Dec;17(4):367-73. doi: 10.1023/a:1021918104127. Metab Brain Dis. 2002. PMID: 12602513 Review.
Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects. ...The pathogenesis of VHE is still unclear, but it has been sugg …
Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated …
Hyperammonemia and valproic acid-induced encephalopathy.
Modjtahedi B, Xiong GL. Modjtahedi B, et al. Am J Psychiatry. 2007 Dec;164(12):1912-3; author reply 1913-4. doi: 10.1176/appi.ajp.2007.07081270. Am J Psychiatry. 2007. PMID: 18056251 No abstract available.
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC. Tseng YL, et al. Medicine (Baltimore). 2014 Sep;93(11):e66. doi: 10.1097/MD.0000000000000066. Medicine (Baltimore). 2014. PMID: 25192484 Free PMC article.
Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy. ...An increase of 1 mg in the dosage of VPA increased the risk of hyperammonemia by 0.1%. In addition, combination treatment with liver enzyme indu …
Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy. ...An increase …
Valproate-induced hyperammonemic encephalopathy.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Segura-Bruna N, et al. Acta Neurol Scand. 2006 Jul;114(1):1-7. doi: 10.1111/j.1600-0404.2006.00655.x. Acta Neurol Scand. 2006. PMID: 16774619 Review.
Polytherapy with several drugs, such as phenobarbital and topiramate, seems to contribute to hyperammonemia. Hyperammonemia leads to an increase in the glutamine level in the brain, which produces astrocyte swelling and cerebral edema. ...These EEG findings, …
Polytherapy with several drugs, such as phenobarbital and topiramate, seems to contribute to hyperammonemia. Hyperammonemia le …
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
Mock CM, Schwetschenau KH. Mock CM, et al. Am J Health Syst Pharm. 2012 Jan 1;69(1):35-9. doi: 10.2146/ajhp110049. Am J Health Syst Pharm. 2012. PMID: 22180549 Review.
PURPOSE: The use of levocarnitine for the treatment of valproic-acid-induced hyperammonemic encephalopathy (VHE) is reviewed. ...A lack of carnitine is thought to contribute to hyperammonemia. Valproic acid is thought to increase renal …
PURPOSE: The use of levocarnitine for the treatment of valproic-acid-induced hyperammonemic encephalopathy (VHE) is rev …
159 results